{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:14:03Z","timestamp":1790788443454,"version":"4.1.0"},"reference-count":12,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T00:00:00Z","timestamp":1458259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:p>The primary objective of treatment in essential thrombocythemia (ET) is to prevent thromboembolic complications. In this regard, advanced age and thrombosis history have long distinguished \u201clow\u201d from \u201chigh\u201d risk patients. More recently, <jats:italic>JAK2<\/jats:italic>V617F and cardiovascular (CV) risk factors were identified as additional modifiers, leading to the development of a 3\u2010tiered International Prognostic Score of Thrombosis for ET (IPSET\u2010thrombosis): \u201clow,\u201d \u201cintermediate,\u201d and \u201chigh\u201d. The international data set used to develop IPSET\u2010thrombosis was recently re\u2010analyzed in order to quantify the additional pro\u2010thrombotic effect of <jats:italic>JAK2<\/jats:italic>V617F and CV risk factors in specific risk subcategories. The revised IPSET\u2010thrombosis identified four risk categories based on three adverse variables (thrombosis history, age &gt;60 years and <jats:italic>JAK2<\/jats:italic>V617F): very low (no adverse features), low (presence of <jats:italic>JAK2<\/jats:italic>V617F), intermediate (age &gt;60 years) and high (presence of thrombosis history or presence of both advanced age and <jats:italic>JAK2<\/jats:italic>V617F). In this study of 585 patients with ET (median age 68 years; 61% female), we validated the revised IPSET\u2010thrombosis by confirming significant differences in thrombosis risk between \u201cvery low\u201d and \u201clow\u201d (HR 2.4, 95% CI 1.1\u2009\u2212\u20095.3) and between \u201cintermediate\u201d and \u201chigh\u201d (HR 2.3, 95% CI 1.1\u2009\u2212\u20095.2) risk patients. Furthermore, in multivariable analysis, only <jats:italic>JAK2<\/jats:italic>V617F (HR=1.8, CI= 1.07\u2009\u2212\u20092.94) and history of thrombosis (HR=2.1, CI= 1.20\u2009\u2212\u20093.58) were independently predictive of future thrombotic events. The revised IPSET\u2010thrombosis needs confirmation in prospective studies, especially in terms of risk\u2010adapted therapy that includes the need for aspirin therapy in very low risk, twice\u2010daily aspirin therapy for low risk and cytoreductive therapy for low or intermediate risk patients. Am. J. Hematol. 91:390\u2013394, 2016. \u00a9 2016 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.24293","type":"journal-article","created":{"date-parts":[[2016,1,22]],"date-time":"2016-01-22T13:51:57Z","timestamp":1453470717000},"page":"390-394","source":"Crossref","is-referenced-by-count":145,"title":["Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (<scp>IPSET<\/scp>\u2010thrombosis) in 585 Mayo clinic patients"],"prefix":"10.1002","volume":"91","author":[{"given":"Mahnur","family":"Haider","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terra","family":"Lasho","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed K.","family":"Abou Hussein","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoseph C.","family":"Elala","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Hanson","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Department of Laboratory Medicine and Pathology Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,3,18]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23895"},{"key":"e_1_2_5_3_1","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.64","article-title":"Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis","volume":"5","author":"Barbui T","year":"2015","journal-title":"Blood Cancer J"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.05.014"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-579136"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.89"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.94"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-444067"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24037"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-339002"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.02.004"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12275"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-263319"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24293","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24293","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24293","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T09:16:14Z","timestamp":1695546974000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,18]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1002\/ajh.24293"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24293","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,18]]}}}